ClinicalTrials.gov
ClinicalTrials.gov Menu

Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00468988
Recruitment Status : Completed
First Posted : May 3, 2007
Last Update Posted : May 25, 2012
Sponsor:
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
Compare the effect of Xalatan with benzalkonium chloride on the ocular surface to those effects observed with Travatan Z without benzalkonium chloride after a single dose

Condition or disease Intervention/treatment Phase
Glaucoma Drug: Travatan® Z Drug: Xalatan® Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
Study Start Date : May 2007
Actual Primary Completion Date : July 2007
Actual Study Completion Date : July 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Tear Break Up Time [ Time Frame: Day ]

Secondary Outcome Measures :
  1. Safety [ Time Frame: Onset ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma

Exclusion Criteria:

  • Age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00468988


Locations
United States, Florida
Orlando
Orlando, Florida, United States, 32801
Sponsors and Collaborators
Alcon Research
Investigators
Study Director: Mark Jasek, PhD Alcon Research

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00468988     History of Changes
Other Study ID Numbers: SMA-06-21
First Posted: May 3, 2007    Key Record Dates
Last Update Posted: May 25, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Latanoprost
Travoprost
Benzalkonium Compounds
Antihypertensive Agents
Anti-Infective Agents, Local
Anti-Infective Agents